The state of California currently has 945 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279
Recruiting
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Glioblastoma, Melanoma Stage IV, Melanoma Recurrent, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Register for Updates
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
NCT05787639
Recruiting
The majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. However, targeting tumors with stereotactic radiation in combination with immunotherapy while sparing draining lymphatics enhances anticancer immunity, resulting in dramatic response in HPV (Human Papilloma Virus) virus related cancers of the throat. This trial will leverage targeted tumor radiation and immunotherapy in advance of standard surgical therapy to improve the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: UC San Diego Moores Cancer Center, La Jolla, California
Conditions: Oropharynx Cancer
Register for Updates
Stool Sample Collection Study
NCT06294873
Recruiting
The primary objective of this study is to obtain de-identified stool specimens from participants with colonoscopic biopsy-based histopathologic diagnosis of colorectal cancer (CRC) and/or a ≥1 cm colorectal polyp/adenoma/mass found during pre-enrollment colonoscopy that is of sufficient size to require surgical excision or complex colonoscopic polypectomy. The samples will be used for the purpose of research and development of a new molecular diagnostic test for the detection of neoplasms of th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: Associated Gastroenterology Medical Group, Anaheim, California
Conditions: Colorectal Cancer
Register for Updates
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
NCT05527184
Recruiting
IMGN151-1001 is a Phase 1, first in human, open-label dose-escalation and expansion study in adult patients with recurrent endometrial cancer, recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: UCLA, Los Angeles, California
Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Register for Updates
Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
NCT03854110
Recruiting
This is a phase 1 first in human, dose escalation trial of GP-2250 administered in combination with gemcitabine in subjects with advanced pancreatic cancer previously treated with 5-fluorouracil-based chemotherapy. Prior radiosensitization with gemcitabine, the use of 5-fluorouracil, FOLFIRINOX or Nab-paclitaxel/gemcitabine in the neoadjuvant setting, and prior pancreaticoduodenectomy (Whipple procedure) is allowed. If prior treatment with gemcitabine was at therapeutic doses, a minimum of 3 mo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: Hoag Family Cancer Institute, Newport Beach, California
Conditions: Pancreatic Cancer, Adult
Register for Updates
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
NCT05612347
Recruiting
This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.
Gender:
All
Ages:
Between 65 years and 82 years
Trial Updated:
02/26/2024
Locations: Kaiser Permanente Northern California, Walnut Creek, California
Conditions: Colorectal Polyp, Colorectal Neoplasms, Colorectal Adenoma, Colorectal Cancer, Digestive System Disease
Register for Updates
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT03562637
Recruiting
The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H Positive TNBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Moores UCSD Cancer Center, La Jolla, California +2 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823
Recruiting
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California
Conditions: Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
Register for Updates
Focal Therapy for Localized Prostate Cancer
NCT06270043
Recruiting
This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: University of California, San Diego, La Jolla, California
Conditions: Prostate Cancer
Register for Updates
Amivantamab in Adenoid Cystic Carcinoma
NCT05074940
Recruiting
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: UC San Diego Moores Cancer Center, La Jolla, California
Conditions: Salivary Gland Cancer
Register for Updates
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05287113
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/22/2024
Locations: City of Hope National Medical Center, Duarte, California +6 locations
Conditions: Head and Neck Cancer
Register for Updates
Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
NCT05415696
Recruiting
The purpose of this study is to learn if the prostatic artery embolization procedure can reduce urinary tract symptoms in patients with enlarged prostates and prostate cancer.
Gender:
All
Ages:
Between 40 years and 90 years
Trial Updated:
02/22/2024
Locations: Stanford Cancer Center, San Francisco, California
Conditions: Prostate Cancer
Register for Updates